NCT Number: NCT00004288
Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis
OBJECTIVES:
I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 2
About this study
PROTOCOL OUTLINE: Patients are treated with daily olsalazine. The dose is increased each week until the protocol dose is reached.
Supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue unchanged. Concurrent sulfasalazine is prohibited.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Meets modified New York diagnostic criteria
- Active disease, i.e., morning stiffness for more than 30 minutes
- Failed or experienced nonlife-threatening reaction to prior sulfasalazine
- No significant hematologic, hepatic, or renal disease
Treatment and study plan
Sponsors and collaborators
Lead sponsor
National Center for Research Resources (NCRR)
Nih
Collaborators
- University of Rochester
Registry information
Important dates
- Study start
- 1996
- Study completion
- 1999
- First posted
- Oct 19, 1999
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
NCT06250062
Ankylosing Spondylitis, Ankylosis
Beijing, Beijing Municipality, China
View Trial DetailsModeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers
NCT05570656
Ankylosing Spondylitis, Ankylosis
Montpellier, France
View Trial DetailsImpact of Air Pollution on the Course of Inflammatory Rheumatism
NCT05862584
Ankylosing Spondylitis, Ankylosis
Nice, France
View Trial DetailsInterest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
NCT02469753
Ankylosing Spondylitis, Ankylosis
Amiens, France
View Trial Details